Abanan, Mary Joy H.

HRN: 22-82-16  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/25/2023
CEFUROXIME 500MG (TAB)
05/25/2023
06/01/2023
PO
500mg
BID X 7 Days
Pus Cells: 10-12, Bacteria: Moderate
Checking Final Appropriateness 
10/23/2023
CEFUROXIME 1.5GM (VIAL)
10/23/2023
10/25/2023
IV
1.5grams
Q8hrs X 4 Doses
S/P Primary CS; Thickly MSAF
Checking Final Appropriateness 
10/23/2023
CEFUROXIME 500MG (TAB)
10/23/2023
10/30/2023
PO
500mg
BID X 7 Days
S/P Primary CS; Thickly MSAF
Checking Final Appropriateness 
10/23/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/23/2023
10/25/2023
IV
500mg
Q8hrs X 4 Doses
S/P Primary CS; Thickly MSAF
Checking Final Appropriateness 
10/23/2023
METRONIDAZOLE 500MG (TAB)
10/25/2023
10/29/2023
PO
500mg
TID X 5 Days
S/P Primary CS; Thickly MSAF
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: